Companies › Immuneering
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Atebimetinib MEK inhibitor | MAP2K1 | Phase 3 | Pancreatic Cancer | Jun 2028 |
| IMM-1-104 RAS/MAPK pathway inhibitor | – | Phase 1 | Advanced Solid Tumor | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05585320 | IMM-1-104 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2027 |
| NCT07562152 | Atebimetinib | Phase 3 | Pancreatic Cancer | Oncology | Jun 2028 |
Cash of $58m on 2026-09-30; operating cash outflow about $69m a year; runway about 10 months at that burn, to Aug 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Verastem Neonc Technologies Lantern Pharma Kura Oncology Inhibrx Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.